Mega-blockbuster status would be quick and sure for any safe, effective agent that prevents the death and
damage of neurons associated with neurodegenerative diseases. The potential of such a neuroprotectant is one
of the motivations for the 188 companies currently involved in the development of 263 neurological pipeline
agents, despite the plethora of marketed agents for these diseases and disorders. Meanwhile, less-debilitating
neurological disorders that nonetheless affect patients’ quality of life (e.g., migraine, insomnia) also face
signifi cant unmet needs. Today’s pipeline of new molecular entities (NMEs) and reformulations holds a range
of agents with potential to improve treatment and infl uence market dynamics, as well as drive market growth
through 2015.
Questions Answered in This Report
The neurology market experienced steady growth from 2004 through 2008. Which drug classes
contributed most to this increase in sales? Which drug classes are projected to contribute to an
increase or decrease in future sales?
Clinical trial design and end points are a signifi cant constraint on drug development and market growth in
the neurology indication. Which neurology indications are particularly affected by these constraints?
What specifi c effects do these constraints have on the market?
The development of a safe, effi cacious neuroprotectant is the elusive “holy grail” in the neurology market.
Why is the development of a neuroprotectant so tantalizing to the neurology fi eld? What barriers have
prevented the development and launch of a successful neuroprotectant? Which companies have latestage
neuroprotectants in the pipeline?
The neurology market is signifi cant in terms of sales and is projected to continue growing in the near future.
Which companies are the current market leaders, and which companies are projected to be the market
leaders in 2015? Which companies are attempting to enter, grow, or protect their position in this
market? Which indications will drive the majority of the growth?
Scope
The neurology pipeline: Number of agents in development; disease focus; NMEs versus
reformulations; formulations by disease; drug targets; phase analysis; development by company
type; number of agents by phase; number of agents by disease; profi les of GlaxoSmithKline, Roche,
and Eli Lilly.
Historical and projected neurology sales: 2004-2015 sales; leading drug classes; current and
(0 items)
